# A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin

> **NCT04118842** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Savolitinib
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT04118842
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2020-02-26
- **Final completion:** 2020-02-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04118842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04118842, "A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04118842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*